A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With Menopause
NIRVANA
A Randomized, Parallel-group Treatment, Phase 2, Double-blind Pilot Study to Investigate the Efficacy and Safety of Elinzanetant Compared With Placebo for Treatment of Sleep Disturbances Associated With Menopause.
Other study identifiers
Sponsor study identifier
Secondary identifiers
REGISTRY · CTIS (EU)
NIH
interventional
110
7 countries
40
Study Start
November 8, 2023
Actual (reported)Primary Completion
August 22, 2024
Actual (reported)Study Completion
November 7, 2024
Actual (reported)Brief Summary
Researchers are looking for a better way to treat women who have sleep disturbances associated with menopause. Menopause is part of a natural aging process and happens when women's menstrual cycles, also called periods, stop. Sleep disturbances, for example, frequent waking up at night, are a common and bothersome symptom associated with menopause that affects women's quality of life. The study treatment Elinzanetant (also called BAY 3427080) is under development to treat symptoms like hot flashes which are caused by hormonal changes associated with menopause. It may block the activity of a protein that has been found to contribute to sleep disturbances. The main purpose of this study is to learn how does elinzanetant affect sleep disturbances associated with menopause as measured on a sleep test called polysomnography (PSG) as compared with placebo. For this, the researchers will analyze
- change in the total number of minutes a participant wakes up at night after going to sleep after 4 weeks of treatment compared to before treatment
- change in the total number of minutes a participant wakes up at night after going to sleep after 12 weeks of treatment compared to before treatment
- change in the participant's total time asleep while in bed after 4 and 12 weeks of treatment compared to before treatment. The study participants will be randomly (by chance) assigned to one of two treatment groups. Dependent on the group, they will take elinzanetant or placebo for 12 weeks. Each participant will be in the study for approximately 22 weeks (plus potential washout period), including a screening phase of up to 6 weeks, 12 weeks of treatment, and a follow up phase of 4 weeks after the end of treatment. 5 visits to the study site are planned. During the study, the doctors and their study team will:
- take blood and urine samples
- do physical examinations
- check vital signs
- do sleep tests
- use an electronic hand-held device to record sleep quality and hot flashes at home An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatments.
Registry Overview
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
- Recruitment status
- completed
- Actual enrollment (reported)
- 110 participants
- Study completion date
November 7, 2024
Actual (reported)- Listed locations
- 7 countries · 40 sites
Trial Relationships
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Study Timeline
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
First Submitted
October 27, 2023
Actual (reported)First Posted
November 1, 2023
Actual (reported)Study Start
November 8, 2023
Actual (reported)Primary Completion
August 22, 2024
Actual (reported)Study Completion
November 7, 2024
Actual (reported)Results Posted
November 10, 2025
Actual (reported)
- Last Updated
- November 10, 2025
- Status Verified
- October 2025
- Results QC Date
- October 28, 2025
- Last Update Submitted
- October 28, 2025